NO20075989L - Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom - Google Patents

Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom

Info

Publication number
NO20075989L
NO20075989L NO20075989A NO20075989A NO20075989L NO 20075989 L NO20075989 L NO 20075989L NO 20075989 A NO20075989 A NO 20075989A NO 20075989 A NO20075989 A NO 20075989A NO 20075989 L NO20075989 L NO 20075989L
Authority
NO
Norway
Prior art keywords
agomelatine
smith
treatment
drugs intended
magenis syndrome
Prior art date
Application number
NO20075989A
Other languages
English (en)
Other versions
NO338951B1 (no
Inventor
Elisabeth Mocaer
Agnes Fabiano
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075989(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20075989L publication Critical patent/NO20075989L/no
Publication of NO338951B1 publication Critical patent/NO338951B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Primary Cells (AREA)
  • Connection Of Batteries Or Terminals (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av agomelatin, eller N-[2-(7-metoksy-1-naftyl)etyl]acetamid, for å oppnå medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom. - 1 -
NO20075989A 2006-11-24 2007-11-23 Anvendelse av agomelatin for å oppnå medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom NO338951B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610296A FR2908995B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis

Publications (2)

Publication Number Publication Date
NO20075989L true NO20075989L (no) 2008-05-26
NO338951B1 NO338951B1 (no) 2016-11-07

Family

ID=38229648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075989A NO338951B1 (no) 2006-11-24 2007-11-23 Anvendelse av agomelatin for å oppnå medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom

Country Status (38)

Country Link
US (1) US20080132577A1 (no)
EP (1) EP1929999B1 (no)
JP (1) JP2008127395A (no)
KR (2) KR20080047299A (no)
CN (1) CN101194901A (no)
AR (1) AR063896A1 (no)
AT (1) ATE501717T1 (no)
AU (1) AU2007234614B2 (no)
BR (1) BRPI0704453A2 (no)
CA (1) CA2610638C (no)
CL (1) CL2007003396A1 (no)
CY (1) CY1111430T1 (no)
DE (1) DE602007013166D1 (no)
DK (1) DK1929999T3 (no)
EA (1) EA013471B1 (no)
ES (1) ES2363252T3 (no)
FR (1) FR2908995B1 (no)
GE (1) GEP20094746B (no)
HR (1) HRP20110370T1 (no)
JO (1) JO2656B1 (no)
MA (1) MA29523B1 (no)
ME (1) ME01959B (no)
MX (1) MX2007014199A (no)
MY (1) MY145139A (no)
NO (1) NO338951B1 (no)
NZ (1) NZ563684A (no)
PE (1) PE20081347A1 (no)
PL (1) PL1929999T3 (no)
PT (1) PT1929999E (no)
RS (1) RS51676B (no)
SA (1) SA07280635B1 (no)
SG (1) SG143203A1 (no)
SI (1) SI1929999T1 (no)
TW (1) TWI370735B (no)
UA (1) UA94042C2 (no)
UY (1) UY30704A1 (no)
WO (1) WO2008071870A2 (no)
ZA (1) ZA200710103B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
PL2810656T3 (pl) 2013-06-06 2018-01-31 Zentiva Ks Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564202A (en) * 1924-05-20 1925-12-08 Christensen Jens Herman Method of producing water-insoluble multicolored screens
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
ZA200710103B (en) 2008-11-26
EP1929999B1 (fr) 2011-03-16
BRPI0704453A2 (pt) 2009-09-08
DE602007013166D1 (de) 2011-04-28
SA07280635B1 (ar) 2011-10-03
UA94042C2 (ru) 2011-04-11
US20080132577A1 (en) 2008-06-05
SG143203A1 (en) 2008-06-27
PL1929999T3 (pl) 2011-06-30
NO338951B1 (no) 2016-11-07
HRP20110370T1 (hr) 2011-06-30
AU2007234614B2 (en) 2012-06-14
PT1929999E (pt) 2011-04-08
EA013471B1 (ru) 2010-04-30
RS51676B (en) 2011-10-31
CY1111430T1 (el) 2015-08-05
MA29523B1 (fr) 2008-06-02
ATE501717T1 (de) 2011-04-15
KR20110086673A (ko) 2011-07-29
TWI370735B (en) 2012-08-21
KR20080047299A (ko) 2008-05-28
GEP20094746B (en) 2009-07-27
MY145139A (en) 2011-12-30
WO2008071870A3 (fr) 2008-08-14
WO2008071870A2 (fr) 2008-06-19
FR2908995A1 (fr) 2008-05-30
EA200702318A1 (ru) 2008-06-30
SI1929999T1 (sl) 2011-06-30
CA2610638C (fr) 2013-07-30
EP1929999A1 (fr) 2008-06-11
FR2908995B1 (fr) 2009-02-06
ME01959B (me) 2011-10-31
CL2007003396A1 (es) 2008-07-25
TW200829237A (en) 2008-07-16
JO2656B1 (en) 2012-06-17
CA2610638A1 (fr) 2008-05-24
MX2007014199A (es) 2009-02-11
ES2363252T3 (es) 2011-07-28
AU2007234614A1 (en) 2008-06-12
JP2008127395A (ja) 2008-06-05
DK1929999T3 (da) 2011-06-27
CN101194901A (zh) 2008-06-11
PE20081347A1 (es) 2008-11-01
AR063896A1 (es) 2009-02-25
UY30704A1 (es) 2008-01-02
NZ563684A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
NO20071774L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av generalisert angstlidelse
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
EA201200728A1 (ru) Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат
NO20075989L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom
UY29470A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
NO20076002L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi
EA201201123A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
UA112407C2 (uk) Співкристали агомелатіну, спосіб їх виготовлення і фармацевтичні композиції, що їх містять
NO20064048L (no) Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den
CU20070070A7 (es) Composición farmacéutica de agomelatina
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
EA200601450A1 (ru) Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат
TH138902A (th) ผลึกร่วมแบบใหม่ของอะโกเมลาทีน กระบวนการในการเตรียมสารดังกล่าวและองค์ประกอบทางเภสัชกรรมที่ประกอบด้วยสารดังกล่าว
TH97711B (th) การใช้อะโกมีลาทีนในการทำให้มาถึงเวชภัณฑ์ที่มุ่งหมายสำหรับการรักษา Smith-Magenis ซินโดรม
UA88322C2 (ru) Применение агомелатина как единственного активного агента в получении лекарственных средств, предназначенных для лечения генерализованного тревожного расстройства

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees